is a significant clinical problem. Seventy-five patients with CD4 T cell counts õ100/mm 3 were monitored prospectively every 2 months for CMV DNA burden. The target for DNA amplification was a 162-bp fragment from the CMV immediate early gene. CMV DNA burden, at levels of §320 in white blood cells or §32 in plasma (P Å .001), particularly when sustained (P Å .005 and .008, respectively), distinguished patients who developed retinitis from those who remained free of disease. Progression to retinitis was not consistently accompanied by increases in CMV burden, indicating that quantitation of CMV burden beyond threshold levels is not necessary to predict risk for development of retinitis. Virus isolation from WBC, but not urine, was also significantly associated with risk for retinitis (P Å .001).
Retinitis is the most common manifestation of cytomegaloviQuantitation of the CMV burden in blood has the potential to provide reliable information about the risk for progression rus (CMV) tissue-invasive disease in human immunodeficiency to CMV retinitis [9 -14] , and the role of CMV burden as a virus (HIV) -infected patients, occurring in 20% -40% of panecessary correlate for progression to retinitis is being estabtients in the first year after CD4 T cells decline to õ50/mm 3 lished. However, quantitation of CMV burden is still dependent [1] . The improved patient survival resulting from the use of on assays developed by individual investigators, since commerantiretroviral and prophylactic drugs for treatment of opportucial assay kits are not yet available for routine use. The stannistic pathogens has resulted in an increased incidence of CMV dards for either minimum CMV DNA detection levels or extent disease [2] . Whether the decrease in CMV retinitis now being of variability in detection of CMV burden that are crucial for observed as a result of the introduction of the new retrovirus the interpretation of any quantitative DNA amplification assay protease inhibitors will persist remains to be seen [3, 4] . remain undefined. In addition, CMV burden can be assessed The search for surrogate predictive markers for CMV disease in either white blood cells (WBC) or plasma. Which sample has been given new impetus by the availability of potentially provides the best information for predicting risk for impending useful prophylactic drugs for preventing retinitis. The potential CMV disease has not yet been established. In this study, the toxicity, as well as expense, limits their general use. Decisions natural history of CMV burden in both plasma and WBC was regarding the use of the available antiviral agents for prophyanalyzed by quantitative DNA amplification. Quantitative laxis of CMV retinitis [5, 6] would be simplified if patients DNA amplification was compared with recovery of infectious most likely to benefit could be identified. The CD4 T cell CMV from blood and urine, as well as the traditional risk factor counts at low levels between 0 and 50, when retinitis is most of CD4 T cell counts, to clarify the relationship between CMV likely to occur, are not sufficiently accurate to identify those burden and the risk for retinitis in HIV-infected patients with at highest risk for retinitis [7, 8] .
AIDS.
confirmed neurologic CMV) to constitute a separate clinical outcal boundaries for the average of the two points. Samples failing to meet the validity criterion were reanalyzed. Samples with copy come group. Both eyes were examined by an experienced ophthalmologist numbers ú3000 were diluted for reamplification because they approached values outside of the logarithmic phase of the reference at study entry and then every 2 months. Hematologic tests included T cell subset enumeration, complete and differential blood counts, curve.
To determine the lowest copy number in the reference curve and serum chemistry. Citrated blood samples were obtained for both CMV DNA quantification and CMV culture. Urine was also that is genuinely greater than 0, a Monte Carlo study [15] of the 78 OD readings corresponding to 10 copies of CMV DNA was obtained for CMV culture. Traditional CMV tube culture methods with 30 days of observation were used [13] . Most of the patients done. The value of 10 copies of CMV DNA was used since it was the first value of the external standard that reliably represented the had been monitored for at least 4 months with at least 3 test observations. Exceptions were from the group of 29 patients who beginning of the log phase of the reference curve. From the 78 OD values obtained for a copy number of 10, two numbers were died on study, 6 of whom had only 2 observations before death.
A total of 559 WBC and 539 plasma samples were studied chosen at random during 1000 samplings to construct a normal distribution curve of the copy number values. The mean value was during the prospective monitoring of the 75 patients. In addition, 354 WBC and 324 urine samples were cultured for CMV. The 0.85 log 10 and the upper 95% point was 1.24 log 10 based on the distribution of the randomly chosen pairs. Thus, an unknown sammean time { SD of study in months for each of the clinical outcome groups was 15 { 4 for those who remained CMV disple with a value of §17 copies, corresponding to 1.24 log 10 , rejects the hypothesis that the copy number of the unknown is £10 and ease-free, 10 { 6 for those who developed retinitis while on study, and 7 { 4 for patients who died during monitoring. The establishes a functional cutoff for a positive response in the assay. Statistical analysis. Means and SDs were compared by use of mean { SD number of observations was 7 { 2, 6 { 3, and 4 { 2, respectively, for patients who were disease-free, developed analysis of variance on ranks. Differences between patient groups were analyzed by either Student's t or Wilcoxon rank sum test for retinitis, or died.
Quantification of CMV DNA on the basis of reference standards. continuously distributed variables. Fisher's exact test was used for categorical variables. The Kaplan-Meier survival analysis was used CMV burden was quantified by amplifying DNA separately from both WBC and plasma. The extraction of DNA from both WBC to calculate time-to-event for occurrence of CMV retinitis and death, and survival functions were tested for significant differences and plasma of citrated blood samples has been described, together with the methods for amplifying CMV DNA by use of biotinylated by log rank (Mantel-Cox) analysis. All tests were two-tailed. Permutation and bootstrap tests were used to compare the differprimers and the polymerase chain reaction, the construction of the CMV DNA-containing plasmids that were the external (p162) and ences in slopes (S) of fitted regression lines [16] . For comparison of S between 2 groups of subject size N1 and N2, all subjects internal (p128) controls for amplification, and the hybridization methods used to quantify the CMV DNA by the optical density were considered together (N1 / N2), and observations were randomly drawn that equaled N1 to produce a hypothetical N1 group. (OD) of the amplified products [12, 13] . For this study, each patient sample was amplified in duplicate. CMV burden is reported either
The remaining values constituted a second hypothetical N2 group. Sampling was done 100 times for each group with a new test per 25 mL of plasma or 1 mg of WBC DNA. The DNA isolation procedure (Qiagen, Carlsbad, CA) used for both plasma and WBC statistic being generated with each permutation. The permutation test P is the proportion of the 100 new test statistics that exceed gave recovery of 80%-90% of input DNA, as determined in reconstruction experiments. As previously reported, the quantities of the original value of S. Small P values, such as .05, are considered as evidence against the null hypothesis of no difference between DNA amplified from either WBC or plasma were comparable in that they were equivalent to a starting volume of 40 mL of whole the 2 groups being tested. blood [12] .
A reference curve, used for extrapolation of the copy number
Results
from patient samples, was generated in every assay by amplifying known ratios of p162 to p128 plasmid DNA. After diagnosis of retinitis, participation in the study ended and of copy numbers that encompassed the interpolation of a patient no further clinical follow-up was done. Patients who remained sample copy number from the reference curve, curves were fitted free of retinitis were monitored clinically for an additional 6 to the mean, /2 SD, and 02 SD of each reference copy number. months after cessation of study participation. Only those who
The average value of the copy number from duplicate analysis of survived the poststudy clinical monitoring were included in the the patient samples was used to interpolate copy number from the disease-free group. Patients who had been disease-free during mean of the reference curves. Based on the SD obtained at the virologic monitoring, but either died or developed retinitis during different reference points on the scale, the probability of falsely the post-virologic monitoring, were shifted to the relevant clinirejecting an authentic sample pair was calculated. The probability cal outcome group and withdrawn from the disease-free catethat any pair of values from a normal standard distribution would gory. The frequencies of both retinitis (25%) and mortality (36%) exceed 4 SD was found to be .005. Conditions for rejection included duplicate values that did not lie within the expected statistiare consistent with those reported in other studies [1, 17] .
The majority of the baseline characteristics of the 3 groups of CMV copy numbers in both WBC and plasma during prospective monitoring is shown in figure 1. Copy numbers of were similar (table 1) . Exceptions were that fewer of the patients who developed retinitis were being treated with zidovu-CMV DNA detected during monitoring encompassed a range of values of nearly 6 log 10 . Slopes of the regression lines dine at time of entry into study compared with the other 2 groups (P Å .01). Patients who died during study had lower showing progression of copy numbers to retinitis were significantly different when retinitis patients were compared with the Karnofsky scores (P õ .001), diagnoses of AIDS by opportunistic infection rather than by CD4 T cell counts of õ200/mm 3 no-disease group (P Å .02 for WBC, P Å .01 for plasma). However, no significant differences were noted when retinitis (P Å .03), and lower CD4 and CD8 T cell counts at entry (P Å .001).
patients were compared with patients who died (P Å .15 for WBC and 0.45 for plasma). Differences in slopes were noted The use of antiretroviral drugs didanosine, zalcitabine, zidovudine, stavudine, and lamivudine during the times the patients when the CMV burden in plasma (P Å .01) but not WBC (P Å .23) was compared in patients who died and in those were tested for CMV burden did not differ among the groups (P Å .99, x 2 , data not shown). Only 7 of the 75 study patients with no disease. Despite the differences in the slopes of the regression lines among the 3 clinical outcome groups, there were treated with protease inhibitors late in the monitoring period (data not shown); during clinical follow-up, 2 of these was considerable overlap in the distribution of CMV DNA copy numbers during progression to the terminal event. patients died, 2 developed retinitis, and 3 were event-free. While increases in CD4 T cell counts were observed in these By use of WBC to monitor CMV burden during progression to retinitis, 8 of 19 patients had increases in CMV DNA that 7 patients, none exceeded 100.
Distribution of CMV copy numbers during prospective moniwere greater than the expected variability of the previous observation, but only 1 of those 8 had the highest CMV burden toring according to clinical outcome group. The distribution before retinitis. For plasma CMV DNA burden, 4 of 19 had Performance characteristics of CMV DNA amplification tests compared with CMV culture and CD4 T cell counts increases before retinitis, and the maximum copy number observed during monitoring occurred before retinitis in 2 of 4 for predicting CMV retinitis. Because of the overlap in the distribution of CMV DNA copy numbers during prospective patients. At the time of retinitis, only a single patient was negative for evidence of CMV DNA in WBC, compared with monitoring, the traditional performance characteristics of the CMV DNA amplification assay, using both WBC and plasma, 5 of 19 who had õ17 copies present in plasma (the minimum copy number associated with a positive response).
were used to identify a range of copies associated with progression to CMV retinitis. Performance characteristics for the As expected, there was loss of CD4 and CD8 T cells in all patient groups during monitoring; however, analysis of regresfour copy number cutoff values that consistently constituted the linear portion of the external reference standard are shown sion slopes indicated that the rate of loss was similar in all 3 clinical outcome groups.
(table 2), since calculations with copy numbers beyond these cutoff points produced values that approached plateaus. SensiLack of relationship between the magnitude of the CMV DNA copy numbers during monitoring and risk for CMV retinitis or tivity, specificity, positive and negative predictive value, and accuracy [18] were used to evaluate quantitative CMV DNA death. The relationship of the maximum copy number attained during monitoring to risk for retinitis is shown in figure amplification, CMV isolation, and CD4 T cell counts as correlates of risk for CMV retinitis. For CMV burden, the patients 2. The total numbers of patients with more than a given copy number in either WBC or plasma were counted and the percentwere classified as either positive or negative if they attained, as a maximum, at least that copy number (or more) during age of patients within that group who developed retinitis was calculated. The slopes of the regression lines, as assessed by prospective monitoring for each of the cutoff values shown in table 2. The 27 patients who died on study were not in-CMV load in either WBC or plasma, were not significantly different from 0, showing that no correlation existed between cluded for this analysis. Symptomatic CMV disease could not be ruled out as a cause of death in these patients, since eyes increasing copy number and either development of retinitis or death.
were not examined postmortem. In addition, CMV DNA copy / 9d39$$no17 09-29-97 14:52:07 jinfa UC: J Infect
When the performance characteristics of CMV isolation and CD4 T cell counts were determined, the specificity and positive and negative predictive value of CMV isolation from WBC but not from urine were comparable to CMV DNA amplification assays in sensitivity and negative predictive value. A CD4 T cell count õ50/mm 3 was sensitive for predicting risk for retinitis (88%) but had both low (46%) positive predictive value and low accuracy (56%).
Because the performance characteristic of accuracy reflects the number of true-positive and -negative results among the study population [18] , the copy numbers that gave high test accuracy ( §320 copies in WBC, §32 copies in plasma, table 2) were chosen to be used as threshold values for grouping patients within each of the 3 clinical outcome groups, as shown in figure 3 .
The mean regression line for copy numbers in patients who progressed to retinitis crossed the threshold risk level of §320 copies at 6 months before diagnosis for retinitis when WBC were monitored, compared with 4 months for §32 copies for plasma (figure 1). In contrast, the mean regression line for copy numbers in patients who remained free of CMV disease during the study never surpassed the threshold risk copy number, irrespective of whether plasma or WBC DNA were amplified.
Association of CMV DNA copy numbers with clinical outcome during prospective monitoring. When the CMV burden from those who developed retinitis (P Å .001). When the entire % of patients who either progressed to retinitis or died (y axis) was then calculated for each copy number (x axis) as amplified from either patient cohort was analyzed, 14 of 19 developed retinitis with WBC or plasma. Regression analysis is represented by dotted lines. §32 copies in plasma while 21 of 56 patients had §32 copies without developing retinitis. These groups were significantly different (x 2 analysis; P Å .007). Fifty percent of the patients who died while being monitored had risk copy numbers of numbers detected at the time of retinitis diagnosis were excluded from the analysis.
CMV DNA in both plasma and WBC; however, 50% who were CMV burden -negative also died during monitoring. The use of WBC DNA to detect CMV burden provided a more sensitive test at all cutoff values than did the use of To evaluate the duration of CMV burden as a risk factor, the frequency of positive tests that exceeded the threshold copy plasma. Sensitivity using WBC to amplify CMV DNA approached 95% at a cutoff of ú100 copies. However, specificity, numbers for the entire study period was determined (24% for WBC and 18% for plasma). The number of patients in each or the ability to detect the true-negative component of those who are disease-free, was highest for plasma and increased clinical outcome group who exceeded the overall population frequency were scored as test-positive. A single determination with increasing copy numbers as cutoff points. The positive predictive value, which defines those who are both diseaseof CMV burden in WBC was only marginally significant (P Å .07) for distinguishing patients who progressed to retinitis and test-positive among the entire population of test-positive patients, was somewhat higher for plasma than for WBC DNA.
from those who remained retinitis-free. However, sustaining the risk copy number was significantly associated with both The highest positive predictive value (81%) occurred at the level of §320 copies of plasma DNA. The negative predictive retinitis (P Å .005 and .0008 for WBC and plasma, respectively, x 2 analysis) and death (P Å .011 and 0.0003 for WBC value was similar for both WBC and plasma over the entire range of cutoff values. and plasma, respectively).
Isolation of CMV occurred with significantly higher freAccuracy for predicting retinitis, which reflects the ratio of the total number of true-positive and true-negative results to quency in patients who developed retinitis than in those who remained disease-free (P Å .001) and was also more likely the entire patient population [18] , was comparable for detection of §32 copies of CMV DNA in plasma (72%), §320 copies from patients who developed retinitis than from those who died on study (P Å .03). CMV was isolated from WBC of a similar in WBC (63%), and isolation of CMV from WBC.
/ 9d39$$no17
09-29-97 14:52:07 jinfa UC: J Infect number of patients with CMV burden in WBC who progressed The clinical outcome defined by CD4 T cell counts of õ50 was of little value for distinguishing patients who developed to retinitis (7/12 for isolation vs. 5/14 for CMV burden). In contrast, fewer patients with CMV burden who did not progress retinitis from those who either remained retinitis-free or died during study. About 30% of the patients who completed monito retinitis had infectious CMV in WBC (5/24 vs. 13/16; P Å .045; not shown). CMV isolation from urine was similar toring with no CMV disease had CD4 T cell counts ú50 but õ100 at some time during monitoring. As expected, signifiin all 3 clinical outcome groups. 
09-29-97 14:52:07 jinfa UC: J Infect cantly more patients who died while on study than patients den in plasma at entry. Progression to mortality in patients attaining CMV threshold levels was not statistically different who remained disease-free consistently had õ50 CD4 T cells.
The four virologic risk factors (ú32 copies in plasma, susfrom those who never attained risk levels of CMV burden during monitoring (P Å .7 for plasma). However, CMV DNA tained copies in WBC and plasma, and CMV culture from WBC) shown on the x axis of figure 3 as well and the five threshold risk copies in plasma were significantly associated with progression to retinitis (P Å .03). Data showing a lack of clinical risk factors (table 1; Karnofsky score õ70, diagnosis of AIDS by opportunistic infection, CD4 T cells õ50, CD8 T association between ú320 copies of CMV DNA in WBC and progression to death and a positive association between §320 cells õ715, and no zidovudine at study entry) were counted for each patient, and the means and standard deviations of the copies in WBC and retinitis were also observed (not shown). total number of the risk factors within each patient group were calculated. The mean { SD of the risk factors was 5.6 { 1.3 Discussion for retinitis patients, 4.1 { 1.4 for patients who died on study, and 2.1 { 1.7 for patients who were free of CMV-associated This study provides prospective evidence that detection of CMV DNA in either WBC or plasma can predict risk for diseases during monitoring. All groups were significantly different from each other (P £ .005, Student's t test).
CMV retinitis in HIV-infected patients with CD4 T cell counts õ100/mm 3 . However, quantification of CMV burden, beyond By use of the variables shown in table 1 documenting baseline characteristics of patients at time of entry into study, the defining a threshold risk copy number, does not consistently predict clinical outcome. entire cohort was divided into those who either had and had not attained or sustained ú32 copies of CMV DNA in plasma Both plasma and WBC were used to quantify CMV burden in blood to evaluate the relative merits of testing each one for or ú320 copies of CMV DNA in WBC. Either the number of patients in each variable group or the mean { SD for each predicting retinitis. The negative predictive values were similar for both plasma and WBC, indicating that absence of CMV parameter was calculated, as appropriate. There were no significant differences in any of the baseline characteristics that burden correlates well with failure to develop retinitis. The positive predictive value and specificity of CMV burden in related in a significant way to whether the threshold copy numbers were attained during monitoring. plasma were somewhat higher than for WBC, pointing to its value for assessing retinitis risk. However, the limitation of the Predictive value of CMV DNA copy number for estimating temporal progression to either death or retinitis. Because of use of plasma is the relatively low sensitivity compared with WBC and the low plasma threshold values (32 copies) that the frequency with which risk levels of CMV burden were observed in patients who died while on study, but with no indicate risk. In our system, there was a 70% variability defining the statistically significant boundaries of copy numbers clinical evidence of symptomatic CMV disease, the time of progression to death in patients with and without CMV thresh-õ100. Since detection of low copy numbers is inherently more variable than detection of high copy numbers, quantitation of old burden levels was analyzed. Patients who either entered or attained the CMV threshold risk copy number in plasma during samples such as plasma, which in general have less CMV burden than WBC [10, 12] , could be inaccurate or inconsistent monitoring were compared to those who never exceeded 32 copies during study (figure 4). Twelve percent had CMV buror have a high false-negative rate when close to the limits of Figure 4 . Kaplan-Meier survival curves of HIV-infected patients for either retinitis or death. Patients were grouped according to whether they did or did not attain threshold risk copy number of CMV DNA in plasma during monitoring. Baseline (0) event, as shown on x axis, was entry into study. Survival was calculated using entire patient cohort (75) for both retinitis and death as clinical end points. Differences in survival groups were calculated by log rank (Mantel-Cox) analysis and showed that patients with ú32 copies in plasma were more likely to develop retinitis than were those with õ32 copies (P Å .03). Progression to death was not significantly associated with CMV DNA copies ú32 (P Å .7).
/ 9d39$$no17 09-29-97 14:52:07 jinfa UC: J Infect detection of the assay. A 33% incidence of retinitis in AIDS CD4 T cell depletion that is associated with advanced HIV infection [20] is well-defined by measurements of HIV loads patients with õ100 copies in plasma has also recently been reported [14] . While amplification of CMV DNA from plasma in the periphery. In contrast, many factors determine whether the eye becomes infected by CMV after a minimum CMV is very specific for predicting risk for retinitis, whether the low sensitivity of the currently available methods will limit its use burden is attained in the periphery. The time of diagnosis of symptomatic CMV retinitis following attainment of threshold in future studies for evaluating effects of antiviral drugs in vivo remains to be determined. Although amplification of CMV CMV burden varied widely among the study patients (figure 4). The penetration of the blood-eye barrier by WBC is likely to DNA burden using plasma is convenient for initial evaluation of risk for retinitis, the use of WBC, which consistently have be governed by events associated with a normal inflammatory response, such as the phenotype and quantity of CMV-infected a higher detectable CMV burden compared on a whole bloodequivalent basis to plasma, may provide a better target for WBC, as well as presence of appropriate cellular adhesion molecules necessary for WBC -endothelial cell contact. Also, monitoring the impact in vivo of antiviral drug therapy.
The ability to identify high-risk patients on the basis of the ability of different CMV strains to replicate in the ocular environment may be a factor in progression to retinitis [21] . threshold copy numbers, provided the assay has an adequate sensitivity, should simplify the development and regulatory Furthermore, the finding in this study, as well as in other studies [14] , that some patients have maximum CMV burden before approval of commercial assays that can be used in clinical practice. Given an assay of sufficient sensitivity (e.g., £17
retinitis indicates that the continued presence of CMV in the peripheral circulation, after the eye becomes infected, does not copies as defined by our data), a positive or negative result at the threshold risk level should suffice to classify the patient reflect ocular events leading to retinitis. The duration of exposure to CMV burden, as shown in this study, appears to be an risk status using either plasma or WBC as targets for amplification. No commercial assays have yet been introduced that meet important component of risk for CMV retinitis, since multiple positive observations in either WBC or plasma during prospecthis standard.
In this study, the cutoff values (32 for plasma DNA and 320 tive monitoring were associated with higher risk for retinitis than single threshold risk observations. for WBC DNA) that associate with risk for retinitis were defined, along with the range of variability that is acceptable for CMV culture from WBC was useful in this study, when combined with CMV burden determination, for defining pavalidation of patient sample copy numbers. However, the copy numbers that are reported to associate with retinitis risk varies tients at highest risk for retinitis. Virus isolation has fallen from favor in diagnosis because of the difficulty and low frequency among laboratories [14] . Differences in gene targets, amplification conditions, detection methods that do not include hybridof recovering infectious CMV from WBC by traditional methods of tube culture and because of the low sensitivity of the ization of the amplification product to a specific probe to ensure specificity, and methods for calculating copy numbers prevent popular shell vial method [22] . Culture of CMV from either blood or urine as a single assay method for predicting retinitis the direct comparison among laboratories. Information regarding the minimum copy number that represents a statistically has been reported to be inconclusive [23, 24] . In this study, isolation of CMV was the single factor that, in patients with significant positive value as well as variability of detection of reference copies has not been provided for many of the pubcomparable CMV burden, distinguished those who progressed to retinitis from those who died (figure 3). Specifically, the lished studies, making comparisons of copy numbers impossible. To minimize differences among laboratories for quantififrequency of CMV isolation from WBC was similar to that of CMV burden in patients who progressed to retinitis; despite cation, a universal standard of CMV DNA that is amplifiable by any CMV primer set could be prepared and quantified in a CMV burden in 45% of WBC of patients with no disease, CMV isolation was rare. The potential usefulness of virus isolareference laboratory and supplied to those using the various DNA amplification methods. The implementation of such a tion from WBC as a supplement to CMV burden for predicting retinitis encourages the improvement of techniques to detect standard would facilitate the comparison of values among laboratories using different quantification methods.
infectious CMV. For example, viral mRNAs encoding either structural or envelope proteins essential for CMV infectivity Our data indicate that factors other than absolute CMV DNA burden determine risk for retinitis. Once a threshold CMV copy [25 -27] that will rapidly indicate the presence of infectious CMV in clinical samples are potentially useful surrogate marknumber is surpassed, further increases are not necessary for progression to retinitis. This conclusion is in general agreement ers for infectivity. Such assays used in conjunction with CMV load may help to improve stratification of patients at highest with the recently published data showing that there was only marginal utility of a quantitative polymerase chain reaction risk for poor clinical outcome. There is no explanation at this time for why, depending on assay compared with a qualitative assay [14] for predicting risk for retinitis. The general approach of quantification of virus whether plasma or WBC is used to measure CMV burden, 25% to 44%, respectively, of the patients with threshold or more load as a diagnostic correlate of increasing risk for disease progression has been given impetus by studies showing the CMV burden remain free of retinitis (figure 3) or why Ç12% -15% of the patients who do not attain the threshold copies importance of HIV load in the development of AIDS [19] . The associated with risk will develop retinitis. The multifactorial tion would be defined to be at risk for retinitis and 45% (34/76) could be excluded from the risk category. Similarly, pathogenesis of CMV retinitis is supported by our data showing that more virologic and clinical risk factors are present in paamong patients with §320 copies, 14 of 42 would develop retinitis, resulting in unnecessary treatment of 37% (28/76) of tients with poor clinical outcome than in those who remain event-free. The finding that a threshold copy number of CMV the population as a whole. However, among patients with õ320 copies of CMV DNA in WBC, there is 15% occurrence of DNA defines risk should provide the basis for future studies that will probe the mechanisms by which progression to retinitis retinitis, or 7% of the entire study population. In summary, this study has demonstrated that CMV DNA can occur over such a broad range of copy number values. Further studies are needed to define the combinations of risk burden in either WBC or plasma precedes risk for retinitis in HIV-infected patients with CD4 T cells õ100/mm 3 . Quantitafactors that are most likely to predict the consequences of CMV reactivation.
tion of CMV burden of §32 by a single observation in plasma, provided the assay is of sufficient sensitivity, or multiple obserIt has long been suspected that chronic CMV infection could contribute to mortality in HIV-infected patients. Chronic CMV vations of CMV burden of §320 in WBC is an improvement over the use of CD4 T cell counts for predicting impending could potentiate immunosuppression in patients with low CD4 T cells even more [28, 29] , thus predisposing to death by other retinitis. However, assessment of CMV burden alone is insufficient at this time for predicting clinical outcome of CMV opportunistic infections or malignancies. While nearly 50% of patients who died during study had threshold levels of CMV reactivation in all patients, probably because of the multifactorial nature of the pathogenesis of CMV retinitis. Some patients burden in either WBC or plasma, a direct association between death and CMV burden could not be shown. Specifically, simiwith risk levels of CMV burden will fail to progress to retinitis. However, absence of CMV burden provides a convenient way lar numbers of patients either with and without CMV burden died (figure 3). In addition, progression to death was the same to identify the majority of the patients who are not at immediate risk for progression to retinitis. Further studies are necessary irrespective of CMV burden (figure 4). These data indicate that CMV burden is unlikely to have a direct role as an independent to define the combination of host and virologic factors that interact to result in CMV retinitis. predictor of death; our data are similar to results showing that no difference in survival was observed between viremic and nonviremic AIDS patients [30] . However, our observations by no means exclude CMV burden as a contributing factor to
